重组改构人肿瘤坏死因子治疗癌性心包积液临床观察  

Clinical Observation of Intrapericardium Administration of rmhTNF to Treat Malignant Hydropericardium in Patients with NSCLC

作　　者：周正贤[1] 吴万梅[1] 张祖蓉[1] 钱红霞[1] 李自全[1] 罗洁[1] 汪霞[1] 

机构地区：[1]四川省肿瘤医院,四川成都610041

出　　处：《河南肿瘤学杂志》2005年第6期404-405,共2页Henan Journal of Oncology

摘　　要：目的临床初步评价重组改构人肿瘤坏死因子(rmhTNF)和顺铂治疗非小细胞肺癌所致心包积液近期疗效和毒副反应.方法选用20例非小细胞肺癌并发癌性心包积液患者,心包穿刺引流积液后注入rmhTNF(5～10)×106U/次,每周给药1次,用顺铂作对照,观察其疗效和毒副反应.结果rmhTNF平均给药2.5次,有效比为9/10,其中CR 6/10,PR 3/10;顺铂对照组平均给药4次,有效比为7/10,其中CR 3/10,PR 4/10.两组发热和胸痛发生率接近,对照组恶心呕吐较重,rmhTNF组未见到明显胃肠道和骨髓抑制毒副反应.结论临床初步评价结果提示大剂量rmhTNF局部给药是治疗癌性心包积液的有效手段,毒副反应可耐受,有深入探讨的必要.Objective To initially evaluate the curative effect and side effects of the new combinant mutant human tumor necrosis factors （rmhTNF） and Cisplatin in hydropericardium caused by NSCLC. Methods All the patients with hydropericardium were infused rmhTNF（5 - 10） × 10^6 U / times （test group） or 50 mg Cisplatin （control group） after pericardial sac drainage. The administration of drugs was once a week. Clinical observation and comparison of the curative effect and side effects between the two groups. Results rmhTNF group was average 2.5 times administration, the effective power was 9/10 （CR 6/10 and PR 3/10）. The control group was average 4 times administration, the effective power was 7/10 （CR 3/ 10 and PR 4/10）. In the side effects of clinical observation, it was no significant difference between the fervescence and the chest complaint, but myelosuppression and nausea had not found in the rmhTNF group. Conclusion The initial results strongly suggest that large dose of rmhTNF may be a new therapy strategy for hydropericardium caused by NSCLC. The evaluation of more cases will be necessary.

关 键 词：RMHTNF 癌性心包积液 心包内灌注 

分 类 号：R732.1[医药卫生—肿瘤] R730.54[医药卫生—临床医学]